Integra LifeSciences Showcases ENT Portfolio and Sponsors Clinical Research at AAO-HNSF 2026
Event summary
- Integra LifeSciences will showcase its ENT technologies at the AAO-HNSF 2026 Annual Meeting in Los Angeles from October 17-20.
- The company will highlight products like the ACCLARENT AERA® Eustachian Tube Treatment and RELIEVA SPINPLUS® Balloon Sinuplasty System.
- Integra is sponsoring new clinical research on chronic ear disease, with a presentation on October 17th by Seilesh C. Babu, M.D.
- ACCLARENT AERA received FDA clearance for pediatric use in December 2023.
The big picture
Integra LifeSciences is leveraging the AAO-HNSF 2026 Annual Meeting to reinforce its position in the ENT market, showcasing a range of innovative technologies. The company's sponsorship of clinical research underscores its commitment to advancing evidence-based care, which is crucial in a sector where long-term patient outcomes and regulatory compliance are paramount. The event also serves as a platform to highlight the strategic importance of its FDA-cleared pediatric indication for the ACCLARENT AERA system, potentially opening new market segments.
What we're watching
- Clinical Validation
- How the outcomes of the Otosclerosis Study Group's research will impact the adoption of Integra's ENT technologies.
- Market Expansion
- The pace at which Integra can expand the use of ACCLARENT AERA in pediatric patients following FDA clearance.
- Competitive Positioning
- Whether Integra can sustain its leadership in ENT technologies amid increasing competition.
Related topics
